|
|
||||||||
J Thorac Cardiovasc Surg 2004;128:489-490
© 2004 The American Association for Thoracic Surgery
Letter to the Editor |
Department of Radiotherapy, Università Cattolica S. Cuore, Rome, Italy
| The first 20% of the full text of this article appears below. |
To the Editor:
We read with great interest the article by Machtay and colleagues,1 which underlines the feasibility of trimodality treatment (concurrent chemoradiation followed by surgical intervention) in the cure of locally advanced nonsmall cell lung cancer (LA-NSCLC) and suggest the use of pathologic downstaging as a predictor for long-term survival.
Several studies have explored the combined trimodality treatment: in the ESSEN2 and SWOG3 trials, patients have been treated with cisplatin plus etoposide (the same drugs used in this study for 22 patients) with a similar
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |